TGFB1 and pulmonary fibrosis: In both bleomycin- and Ad-TGF-β-induced murine pulmonary fibrosis models, saracatinib significantly reduced lung hydroxyproline (an indicator of collagen deposition), improved lung compliance, and attenuated radiographic abnormalities, with efficacy comparable or superior to nintedanib and pirfenidone (Hu et al., 2014; Baselga et al., 2010).